Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Despite marked improvements in treatment, cancer is still the cause of roughly 17% of deaths globally. One reason for this is the lack of early diagnosis — cancers caught early are more treatable. But researchers are making impressive progress.
Increasingly sensitive tests have raised the risk overdiagnosis. Understanding a person’s chance of disease could reduce the harmful side effects of screening.
The analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis, says Catherine Alix-Panabières. The challenge now is to make liquid biopsy a standard clinical tool.
The implementation of screening tests for certain cancers has led to the phenomenon of overdiagnosis, whereby a cancer is diagnosed that would otherwise not go on to cause symptoms or death. This Opinion article discusses the effects of overdiagnosis and emerging strategies to reduce overdiagnosis of indolent cancers through an understanding of tumour biology and the tumour microenvironment.
An artificial intelligence-powered microscope able to detect tumor cells in histopathology slides holds promise for accelerating pathology workflows for cancer diagnosis
A convolutional neural network performs automated prediction of malignancy risk of pulmonary nodules in chest CT scan volumes and improves accuracy of lung cancer screening.
Interval invasive breast cancers diagnosed after a normal mammogram but before the next screening examination have a different tumour biology from that of screen-detected breast cancers, and thus are not detected on mammography. Understanding the genetics and biology of interval invasive cancers could inform better approaches to detection.
Diehn and colleagues report that assaying circulating DNA in patients receiving chemoradiation therapy for non-small-cell lung cancer could identify the patients most likely to benefit from consolidation immunotherapy.
Direct prospective comparison of circulating tumor DNA and tissue biopsy sequencing shows the superiority of liquid biopsies for capturing clinically relevant alterations mediating resistance to targeted therapies in cancer patients.